Analyst Ratings For Puma Biotechnology (NYSE:PBYI)
Today, Leerink Swann reiterated its Outperform rating on Puma Biotechnology (NYSE:PBYI) with a price target of $125.00.
There are 1 hold rating, 7 buy ratings on the stock.
The current consensus rating on Puma Biotechnology (NYSE:PBYI) is Buy (Score: 2.88) with a consensus target price of $111.13 per share, a potential 23.54% upside.
Some recent analyst ratings include
- 8/2/2017-Leerink Swann Reiterated Rating of Outperform.
- 8/1/2017-J P Morgan Chase & Co Reiterated Rating of Buy.
- 7/22/2017-Cowen and Company Reiterated Rating of Outperform.
- 7/21/2017-Bank of America Corporation Reiterated Rating of Buy.
- 7/18/2017-Citigroup Inc. Reiterated Rating of Buy.
- 7/18/2017-Stifel Nicolaus Reiterated Rating of Buy.
Recent Insider Trading Activity For Puma Biotechnology (NYSE:PBYI)
Puma Biotechnology (NYSE:PBYI) has insider ownership of 22.70% and institutional ownership of 80.98%.
- On 7/20/2017 Alan H Auerbach, Insider, sold 13,175 with an average share price of $94.73 per share and the total transaction amounting to $1,248,067.75. View SEC Filing
- On 7/20/2017 Richard Paul Bryce, SVP, sold 1,998 with an average share price of $94.48 per share and the total transaction amounting to $188,771.04. View SEC Filing
- On 7/3/2017 Richard Paul Bryce, SVP, sold 5,000 with an average share price of $87.10 per share and the total transaction amounting to $435,500.00. View SEC Filing
- On 6/12/2017 Adage Capital Partners Gp, L.L, Major Shareholder, sold 247,260 with an average share price of $80.32 per share and the total transaction amounting to $19,859,923.20. View SEC Filing
- On 6/5/2017 Adage Capital Partners Gp, L.L, Major Shareholder, sold 507,128 with an average share price of $87.84 per share and the total transaction amounting to $44,546,123.52. View SEC Filing
- On 5/26/2017 Adage Capital Partners Gp, L.L, Major Shareholder, sold 1,235,700 with an average share price of $75.38 per share and the total transaction amounting to $93,147,066.00. View SEC Filing
- On 2/1/2017 Robert Charnas, Insider, sold 3,008 with an average share price of $31.83 per share and the total transaction amounting to $95,744.64. View SEC Filing
Recent Trading Activity for Puma Biotechnology (NYSE:PBYI)
Shares of Puma Biotechnology closed the previous trading session at 86.75 down -3.20 -3.56% with 2,218,252 shares trading hands.